Kallman syndrome

Kallman syndrome
The structure of GNRH1 (from PDB: 1YY1​)
ICD-10	E23.0
ICD-9	253.4
OMIM	308700 147950 244200 138850 607002
DiseasesDB	7091
eMedicine	med/1216  med/1342
MeSH	D017436

WikiDoc Resources for Kallman syndrome
Articles
Most recent articles on Kallman syndrome Most cited articles on Kallman syndrome Review articles on Kallman syndrome Articles on Kallman syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Kallman syndrome Images of Kallman syndrome Photos of Kallman syndrome Podcasts & MP3s on Kallman syndrome Videos on Kallman syndrome
Evidence Based Medicine
Cochrane Collaboration on Kallman syndrome Bandolier on Kallman syndrome TRIP on Kallman syndrome
Clinical Trials
Ongoing Trials on Kallman syndrome at Clinical Trials.gov Trial results on Kallman syndrome Clinical Trials on Kallman syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Kallman syndrome NICE Guidance on Kallman syndrome NHS PRODIGY Guidance FDA on Kallman syndrome CDC on Kallman syndrome
Books
Books on Kallman syndrome
News
Kallman syndrome in the news Be alerted to news on Kallman syndrome News trends on Kallman syndrome
Commentary
Blogs on Kallman syndrome
Definitions
Definitions of Kallman syndrome
Patient Resources / Community
Patient resources on Kallman syndrome Discussion groups on Kallman syndrome Patient Handouts on Kallman syndrome Directions to Hospitals Treating Kallman syndrome Risk calculators and risk factors for Kallman syndrome
Healthcare Provider Resources
Symptoms of Kallman syndrome Causes & Risk Factors for Kallman syndrome Diagnostic studies for Kallman syndrome Treatment of Kallman syndrome
Continuing Medical Education (CME)
CME Programs on Kallman syndrome
International
Kallman syndrome en Espanol Kallman syndrome en Francais
Business
Kallman syndrome in the Marketplace Patents on Kallman syndrome
Experimental / Informatics
List of terms related to Kallman syndrome

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Kallmann syndrome is an example of hypogonadism (decreased functioning of the sex hormone-producing glands) caused by a deficiency of gonadotropin-releasing hormone (GnRH), which is created by the hypothalamus. Kallmann syndrome is also known as hypothalamic hypogonadism, familial hypogonadism with anosmia, or hypogonadotropic hypogonadism, reflecting its disease mechanism.

Kallmann syndrome is a form of secondary hypogonadism reflecting the fact the primary cause of the defect in sex hormone production lies within the pituitary and hypothalamus rather than a physical defect of the testes or ovaries themselves.

Kallmann syndrome was described in 1944 by Franz Josef Kallmann, a German-American geneticist. However, others - such as the Spanish doctor Aureliano Maestre de San Juan - had noticed a correlation between anosmia and hypogonadism in 1856.

The most well known person who has Kallmann syndrome in modern times is the jazz vocalist Jimmy Scott. In 2004, Canadian writer Brian Brett published a memoir, Uproar's Your Only Music, about growing up with Kallmann syndrome.

Features

Kallmann syndrome is characterized by:

• Hypogonadotropic hypogonadism (a lack of the pituitary hormones LH and FSH)
• Congenital (present from birth) anosmia (complete inability to smell) or hyposmia (decreased ability to smell)

It can occasionally be associated with optic problems, such as colour blindness or optic atrophy, nerve deafness, cleft palate, cryptorchidism, renal agenesis, and mirror movement disorder. However, it is not clear at this time how or if these other problems have the same cause as the hypogonadism and anosmia. These problems are more often present in those without Kallmann syndrome.

Males present with delayed puberty and may have micropenis (although congenital micropenis is not present in the majority of male KS cases).

Females present with delayed puberty (i.e. primary amenorrhea) and lack of secondary sex characteristics, such as breast development.

Diagnosis

The diagnosis is often one of exclusion found during the workup of delayed puberty. The presence of anosmia together with delayed puberty in either boys or girls should suggest Kallmann syndrome.

Pathophysiology

Under normal conditions, GnRH travels from the hypothalamus to the pituitary gland via the hypophyseal portal system, where it triggers production and release of gonadotropins (LH and FSH) from the gonadotropes. When GnRH is low, the pituitary does not create the normal amount of gonadotropins. The gonadotropins normally increase the production of gonadal steroids, so when they are low, these steroids will be low as well.

In Kallmann syndrome, the GnRH neurons do not migrate properly from the olfactory placode to the hypothalamus during development. The olfactory bulbs also fail to form or have hypoplasia, leading to anosmia or hyposmia.

Kallmann syndrome can be inherited as an X-linked recessive trait, in which case there is a defect in the KAL1 gene, which maps to chromosome Xp22.3. KAL encodes a neural cell adhesion molecule, anosmin-1. Anosmin-1 is normally expressed in the brain, facial mesenchyme, mesonephros and metanephros. It is required to promote migration of GnRH neurons into the hypothalamus. It also allows migration of olfactory neurons from the olfactory bulbs to the hypothalamus.

An autosomal dominant gene on chromosome 8 {8p12} (KAL-2 or FGFR-1 (fibroblast growth factor receptor 1)) is thought to cause about 10% of cases. There is some recent evidence to suggest a degree of linkage between the KAL-1 and FGFR-1 genes.

An additional autosomal cause of Kallmann syndrome has been reported by a mutations in the prokineticin receptor-2 gene (PROKR2)(KAL-3) at position 20p13 and its ligand prokineticin 2 (PROK2)(KAL-4) at position 3p21.1. It was noted that mutations in these genes brought about various degrees of olfactory and reproductive dysfunction, but not the other symptoms seen in KAL-1 and KAL-2 forms of Kallmann Syndrome. The authors of the paper suggested that up to 30% of all Kallmann Syndrome cases can be linked to known genetic mutations.

Treatment

Treatment is directed at restoring the deficient hormones -- known as hormone therapy (HT). Males are administered human chorionic gonadotropin (hCG) or testosterone. Females are treated with oestrogen and progestins.

To induce fertility in males or females, GnRH (aka LHRH) is administered by an infusion pump, or hCG/hMG/FSH/LH combinations are administered through regular injections. Fertility is only maintained whilst actually being treated with these hormones. Once fertility treatment stops it is necessary to revert to the normal HRT of testosterone for men and oestrogen + progestins for women.

The main health risk, for both men and women, of untreated Kallmann Syndrome is osteoporosis. Therefore, regular bone density scans (every 2 years or so) are advisable, even if being treated with HRT. Additional medication specifically for osteoporosis is necessary in some cases.

Epidemiology

Kallmann syndrome occurs at a rate of 1 in 10,000 male births and 1 in 50,000 female births. It may be inherited as an X-linked condition, an autosomal dominant condition or as an autosomal recessive condition. Statistics are sparse, but it seems that autosomal dominant is the most common form of heredity.

One recent paper quoted an incidence in males of 0.025%, or 1 in 4,000, with the female incidence being 3 to 5 times less.

Even though mutations in the KAL-1 gene on the X chromosome can cause Kallmann syndrome, only 11-14% of patients with Kallmann syndrome have detectable KAL-1 mutations.

Autosomal dominant mutations have been described with the FGFR-1 (8p12) gene, sometimes referred to as the KAL-2 gene. This is thought to cause about 10% of cases. However, the majority of KS cases (70%) would seem to be the result of autosomal dominant genes even though the identity of those genes is not yet known.

Autosomal recessive mutations of the GnRH receptor gene (4q13.2) have also been reported. This defect appears to produce a wider spectrum of physical symptoms than with the other gene defects, and the defect lies in the ability of the pituitary gland to recognize GnRH, rather than the ability of the hypothalamus to produce GnRH. It is debatable as to whether this is in fact Kallmann syndrome since the GnRH receptor development is not related to anosmia.

There may also be no obvious family history of inheritance (sporadic cases). However, it is possible for Kallmann syndrome genes to be passed on to children of a sporadic case.

Psychological Issues

In some cases, the psychological effects of having this condition can outweigh the significance of any physical symptoms.

The social stigma of being left behind by your peer group at a vital stage of physical and emotional development can leave lasting damage to some people. Some people with Kallmann syndrome find it difficult to fit into social groups and may have trouble in forming relationships both on the physical and emotional level. This might be more profound in people who are diagnosed later in life.

Practical Issues

While the lack of sense of smell may not be important when compared to the lack of sexual development, it does give rise to a few situations where care should be taken. These can include:

Personal hygiene.

Gas leaks within the home. Fitting gas detectors within the home is recommended.

Food & drink spoilage. Extra care should be taken with the expiration dates for food and drink.

External links

• Updated information web site on Kallmann syndrome
• Information web site on Kallmann's syndrome
• Man, 33, seeks puberty The case of Lawrence Koomson a physician who was treated for the condition as filmed in the documentary. (BBC)